RxDoctor Payments Data

Michael Marfice, MD

Family Medicine · Foley, ALNPI 1457989725

Payments from drug & device makers

$1,058in general payments, 2019–2025

Across 49 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$355
  • AstraZeneca$288
  • AbbVie$107
  • Lilly USA, LLC$71
  • Exact Sciences$53
  • Viatris Specialty LLC$36
  • plus $148 from 8 others

What the payments were for

  • Food & beverage$1,058100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,058 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$74,093
Medicare patients
266
Services billed
1,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$194,355
MounjaroTirzepatide45$57,335
JardianceEmpagliflozin32$42,928
EliquisApixaban16$23,758
Repatha SureclickEvolocumab23$19,087
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,169
WegovySemaglutide11$13,840
XareltoRivaroxaban19$13,050
Rosuvastatin Calcium151$2,096
Olmesartan Medoxomil54$1,379
Duloxetine Hcl67$1,334
Famotidine15$1,296
Atorvastatin Calcium109$1,117
Pantoprazole Sodium81$1,033
Tamsulosin Hcl71$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$355$208,195154 claims
Lilly USA, LLCMounjaro$71$57,33545 claims
Boehringer IngelheimJardiance$19$42,92832 claims
AstraZenecaBreztri Aerosphere$288$15,16924 claims
AbbVieSynthroid$107$66911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →